Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis (Prothena Corporation plc)

(Source: Prothena Corporation plc) New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%, respectively, that are consistent with those previously published in the Journal of Clinical Oncology Improvement of peripheral neuropathy was demonstrated by a mean 35% decrease in the Neuropathy Impairment Score-Lower Limb (NIS-LL) in peripheral neuropathy expansion cohort Continued to be safe and well tolerated Dr. Morie A. Gertz, Chair of Internal Medicine at Mayo Clinic, to present data during Prothena's investor conference call and webcast today at 10:30 AM EDT DUBLIN, Ireland, July 05, 2016...